CytomX Therapeutics (NASDAQ:CTMX) Upgraded at StockNews.com

StockNews.com upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a hold rating to a buy rating in a research report report published on Monday morning.

Several other research analysts also recently commented on the company. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Wedbush restated an “outperform” rating and set a $5.00 price target on shares of CytomX Therapeutics in a research note on Friday, March 7th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.02.

CytomX Therapeutics Trading Down 3.5 %

NASDAQ CTMX opened at $0.60 on Monday. The stock has a market cap of $46.86 million, a PE ratio of 3.52 and a beta of 1.05. CytomX Therapeutics has a 12 month low of $0.57 and a 12 month high of $5.85. The company’s 50-day moving average price is $0.82 and its 200-day moving average price is $1.01.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.45. The business had revenue of $38.09 million for the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. As a group, sell-side analysts forecast that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

Hedge funds have recently bought and sold shares of the stock. US Bancorp DE purchased a new position in shares of CytomX Therapeutics in the 3rd quarter valued at $40,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in CytomX Therapeutics by 10.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares during the last quarter. FMR LLC grew its stake in CytomX Therapeutics by 17.3% in the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after purchasing an additional 41,949 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 16,359 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 34,032 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.